Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Issues Earnings Results

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings data on Monday. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06, FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Stock Up 2.8%

NASDAQ:DMRA opened at $30.36 on Wednesday. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33. The stock’s fifty day moving average is $26.70 and its two-hundred day moving average is $26.31. The company has a market capitalization of $1.87 billion, a P/E ratio of -5.44 and a beta of 1.47.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently bought and sold shares of DMRA. Two Sigma Investments LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth about $76,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth approximately $49,000. Connective Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $100,000. Geode Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $266,000. Finally, Remedium Capital Partners LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,772,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DMRA has been the subject of a number of recent research reports. Wedbush increased their price objective on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Finally, Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a “buy” rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.